1. Search Result
Search Result
Results for "

Soluble

" in MCE Product Catalog:

108

Inhibitors & Agonists

8

Screening Libraries

13

Dye Reagents

13

Biochemical Assay Reagents

2

Peptides

1

MCE Kits

3

Inhibitory Antibodies

14

Natural
Products

20

Recombinant Proteins

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-U00453
    Soluble epoxide hydrolase inhibitor

    Epoxide Hydrolase Metabolic Disease Cardiovascular Disease
    Soluble epoxide hydrolase inhibitor is an inhibitor of soluble epoxide hydrolase, and inhibits human soluble epoxide hydrolase (h-sEH) with pIC50 of 8.4, extracted from patent WO 2010096722 A1, example 57.
  • HY-B0512A
    Sulfamerazine sodium salt

    Soluble sulfamerazine

    Bacterial Antibiotic Infection
    Sulfamerazine Sodium is a sulfonamide antibacterial.
  • HY-N0322A
    Cholesterol (Water Soluble)

    Others Others
    Cholesterol Water Soluble can be used for the research of the effects of cholesterol on the potassium currents in inner hair cells (IHCs). Cholesterol is an integral component of the cell membrane and regulates the activity of ion channels in the lipid bilayer.
  • HY-142697
    SGC agonist 1

    Others Cardiovascular Disease
    SGC agonist 1 is a potent agonist of soluble guanylate cyclase (SGC). SGC agonist 1 improves solubility combined with high cell permeability. SGC agonist 1 has the potential for the research of cardiovascular disease (extracted from patent WO2016030354A1, compound 18A).
  • HY-124063
    BI-1935

    Epoxide Hydrolase Cardiovascular Disease
    BI-1935 is a potent soluble epoxide hydrolase (sEH) inhibitor for diseases related to cardiovascular disease.
  • HY-136964
    Sulfo-NHS-Biotin sodium

    Others Others
    Sulfo-NHS-Biotin (sodium) stongly label single SDS-2ME soluble cuticular protein.
  • HY-120494
    sEH inhibitor-1

    Epoxide Hydrolase Inflammation/Immunology
    sEH inhibitor-1 (compound TCPU ) is a potent and oral active inhibitor of sEH (soluble epoxide hydrolase) with IC50s of 0.4 and 5.3 nM in human and murine, respectively.
  • HY-N6875
    Oleuropeinic acid

    Others Metabolic Disease
    oleuropeinic acid is present initially in olive tissues or formed by the thermal treatment, possibly by the oxidation of oleuropein. Oleuropeinic acid is an antioxidant-soluble fiber.
  • HY-D0505A
    Eosin Y disodium

    Acid Red 87

    Others Others
    Eosin Y (disodium) is a soluble acid red dye molecule. Eosin Y has a wide application in organic synthesis as a photoredox catalyst.
  • HY-142698
    SGC agonist 2

    Others Cardiovascular Disease
    SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031).
  • HY-107546
    CFM 1571 hydrochloride

    Guanylate Cyclase Cardiovascular Disease
    CFM 1571 hydrochloride is the stimulator of the nitric oxide receptor, soluble guanylate cyclase (sGC) with an EC50 and IC50 of 5.49 μM and 2.84 μM, respectively. Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). CFM 1571 hydrochloride has the potential for the research of cardiovascular and other diseases.
  • HY-108570
    AUDA

    Epoxide Hydrolase Inflammation/Immunology
    AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively. AUDA has anti-inflammatory activity.
  • HY-17500
    Ataciguat

    HMR-1766

    Guanylate Cyclase Cardiovascular Disease
    Ataciguat (HMR-1766) is a nitric oxide-independent soluble guanylate cyclase (sGC) activator. Ataciguat is able to activate the ferric heme-iron redox form of sGC that stimulate the production of cyclic GMP (cGMP). Ataciguat exhibits vasodilator effects.
  • HY-135653
    EC5026

    BPN-19186

    Epoxide Hydrolase Neurological Disease
    EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain.
  • HY-126326
    SWE101

    Epoxide Hydrolase Metabolic Disease
    SWE101 (compound 22 b) is a potent soluble epoxide hydrolase (sEH)-P inhibitor with IC50s of 4 μM and 2.8 μM for human and rat sEH-P, respectively. SWE101 does not inhibit neither hydrolase nor phosphatase activity of the mouse sEH.
  • HY-145261
    hDHODH-IN-8

    Lactate Dehydrogenase Inflammation/Immunology
    hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 16 nM. hDHODH-IN-8 has potent antiproliferative activity and excellent aqueous solubility. hDHODH-IN-8 has the potential for the research of tumor disease, especially lymphoma.
  • HY-132131
    Vazegepant hydrochloride

    Zavegepant hydrochloride; BHV-3500 hydrochloride

    CGRP Receptor Infection Inflammation/Immunology
    Vazegepant (BHV-3500) hydrochloride is a highly soluble CGRP receptor antagonist (hCGRP Ki= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine. Vazegepant hydrochloride may be helpful in effective management of COVID-19 associated pulmonary inflammation.
  • HY-132298
    TDI-10229

    Adenylate Cyclase Others
    TDI-10229 is a potent and orally bioavailable inhibitor of soluble adenylyl cyclase (sAC, ADCY10). TDI-10229 displays nanomolar inhibition of sAC in both biochemical and cellular assays (IC50 of 195 nM) and exhibits mouse pharmacokinetic properties sufficient to warrant its use as an in vivo tool compound.
  • HY-113974
    trans-AUCB

    t-AUCB

    Epoxide Hydrolase Cancer
    trans-AUCB (t-AUCB) is a potent, orally active and selective soluble epoxide hydrolase (sEH) inhibitor with IC50s of 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively. trans-AUCB has anti-glioma activity.
  • HY-116844
    Glymidine

    Glidiazine

    Others Metabolic Disease
    Glymidine (Glidiazine) is a hypoglycaemic agent. Glymidine is a lipid soluble sulphapyrimidine derivative. Glymidine appears to stimulate insulin release from pancreas. Glymidine is a possible alternative to the sulphonylureas and biguanides for the research of diabetes mellitus.
  • HY-145607
    Zagociguat

    Guanylate Cyclase Cardiovascular Disease
    Zagociguat is the stimulator of soluble guanylate cyclase. Zagociguat increases nitric oxide (NO) signaling leading to an increase in cyclic guanosine monophosphate production. Zagociguat has the potential for the research of noncentral nervous system (CNS) disorders.
  • HY-W127758
    Alginic acid

    Histamine Receptor Apoptosis Autophagy Endocrinology Inflammation/Immunology
    Alginic acid is a natural polysaccharide, which has been widely concerned and applied due to its excellent water solubility, film formation, biodegradability and biocompatibility. Alginic acid induces oxidative stress-mediated hormone secretion disorder, apoptosis and autophagy in mouse granulosa cells and ovaries. Alginic acid has an inhibitory effect on histamine release. Anti-anaphylactic and anti-inflammatory properties.
  • HY-W062836
    BAY 41-8543

    Guanylate Cyclase Cardiovascular Disease
    BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research.
  • HY-121538
    CUDA

    Epoxide Hydrolase PPAR Cardiovascular Disease
    CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease.
  • HY-145833A
    sEH/AChE-IN-4

    Epoxide Hydrolase AChE Cancer Neurological Disease
    sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC50 values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively.
  • HY-17431
    Fosamprenavir Calcium Salt

    GW433908G

    HIV Infection
    Fosamprenavir Calcium Salt (GW433908G) is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility. Anti-HIV infection.
  • HY-78726
    Fosamprenavir

    Amprenavir phosphate; GW 433908

    HIV Infection
    Fosamprenavir (Amprenavir phosphate;GW 433908) is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility. Anti-HIV infection.
  • HY-122131
    XTT sodium

    Others Others
    XTT (sodium) is used to assess cell viability as a function of redox potential. Actively respiring cells convert the water-soluble XTT to a water-soluble, orange colored formazan product.
  • HY-78726S
    Fosamprenavir-d4

    Amprenavir phosphate-d4; GW 433908-d4

    HIV Endogenous Metabolite Infection
    Fosamprenavir-d4 is deuterium labeled Fosamprenavir. Fosamprenavir (Amprenavir phosphate;GW 433908) is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility. Anti-HIV infection.
  • HY-N1014
    11α,12β-Di-O-acetyltenacigenin B

    Others Others
    11α,12β-Di-O-acetyltenacigenin B is a polyoxypregnane compound isolated from the CHCl(3)-soluble fraction of the ethanolic extract of the stem of Marsdenia tenacissima.
  • HY-126437
    Poly-L-lysine hydrobromide

    Others Others
    Poly-L-lysine (hydrochloride) is a water-soluble synthetic polypeptide.
  • HY-100524
    LRE1

    Adenylate Cyclase Cancer
    LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase.
  • HY-12376
    BAY 41-2272

    Guanylate Cyclase Inflammation/Immunology
    BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.
  • HY-D1396
    Br-DAPI

    Others Others
    Br-DAPI is a water-soluble, cell-permeable, DNA-binding photosensitizer.
  • HY-16774
    Vericiguat

    BAY1021189

    Guanylate Cyclase Cardiovascular Disease
    Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.
  • HY-123283
    OXi8007

    Microtubule/Tubulin Cancer
    OXi8007 is a water-soluble phosphate prodrug of OXi8006, a tubulin-binding compound.
  • HY-14181A
    Cinaciguat hydrochloride

    BAY 58-2667 hydrochloride

    Guanylate Cyclase Cardiovascular Disease
    Cinaciguat hydrochloride is a potent soluble guanylate cyclase (GC) activator with EC50 of 15 nM in platelets.
  • HY-A0104
    Hypromellose

    (Hydroxypropyl)methyl cellulose; HPMC; Celacol HPM 5000

    Others Others
    Hypromellose is a hydrophilic, non-ionic cellulose ether used to form swellable-soluble matrices.
  • HY-B1513
    α-Cyclodextrin

    Others Others
    α-Cyclodextrin is a multifunctional, soluble dietary fiber marketed for use as a fiber ingredient.
  • HY-14779
    Riociguat

    BAY 632521

    Guanylate Cyclase Cardiovascular Disease
    Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
  • HY-78237
    Nelociguat

    BAY60-4552

    Guanylate Cyclase Cardiovascular Disease
    Nelociguat (BAY60-4552) is a nitric oxide sensitive soluble guanylate cyclase stimulator.
  • HY-114266
    UC-1728

    t-TUCB

    Epoxide Hydrolase Inflammation/Immunology Cardiovascular Disease
    UC-1728 is a potent rabbit soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 2 nM on rabbit liver.
  • HY-14927
    Lificiguat

    YC-1

    Guanylate Cyclase Cancer
    Lificiguat binds to the β subunit of soluble guanylyl cyclase(sGC) with Kd of 0.6-1.1 μM in the presence of CO.
  • HY-101294
    TPPU

    Epoxide Hydrolase Inflammation/Immunology
    TTPU is a soluble epoxide hydrolase (sEH) inhibitor with IC50 values of 37 and 3.7 nM for monkey and human sEH, respectively.
  • HY-12827
    Sortin1

    Others Others
    Sortin1 is a chemical genetic-hit molecule that causes specific mislocalization of plant and yeast-soluble and membrane vacuolar markers.
  • HY-12339
    NVS-CRF38

    CRFR Endocrinology
    NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility.
  • HY-W013386
    LY83583

    Guanylate Cyclase Inflammation/Immunology
    LY83583 is a cell-permeable and competitive inhibitor of soluble guanylate cyclase (sGC) with an IC50 value of 2 µM.
  • HY-111151
    AR-9281

    APAU

    Epoxide Hydrolase Metabolic Disease
    AR9281 is a potent and selective inhibitor of soluble epoxide hydrolase (s-EH), with potential for the treatment of hypertension and type 2 diabetes.
  • HY-117962A
    BI 703704

    Guanylate Cyclase Metabolic Disease
    BI 703704 is a potent soluble guanylate cyclase (sGC) activator. BI 703704 inhibits the progression of diabetic nephropathy in the ZSF1 rat.
  • HY-146643
    sEH inhibitor-3

    Epoxide Hydrolase Neurological Disease
    sEH inhibitor-3 (compound 35) is a potent and orally active soluble epoxide hydrolase (sEH) inhibitor with a Ki of 0.75 nM for human sEH.
  • HY-N1725
    2-Desoxy-4-epi-pulchellin

    Others Others
    2-Desoxy-4-epi-pulchellin (compound 13) is a compound isolated from dichloromethane-soluble portion of Polygonum hydropiper.
  • HY-135005
    Biliverdin hydrochloride

    Endogenous Metabolite Inflammation/Immunology
    Biliverdin hydrochloride is a tetrapyrrolic, water-soluble compound formed by the breakdown of heme. Biliverdin hydrochloride can upregulate the activity of biliverdin reductase which is an enzyme that is a regulator of the innate immune system.
  • HY-109136
    Runcaciguat

    Guanylate Cyclase Cardiovascular Disease
    Runcaciguat is an orally active stimulator of soluble guanylate cyclase, and is used in the research of cardiovascular and renal diseases combined with selective partial adenosine A1 receptor agonists.
  • HY-12887
    Piclamilast

    RP 73401; RPR 73401

    Phosphodiesterase (PDE) Cancer Inflammation/Immunology
    Piclamilast (RP 73401) is a phosphodiesterase 4 (PDE4) inhibitor, with IC50 values of 16 nM and 2 nM in pig aorta and eosinophil soluble, respectively.
  • HY-101255
    ODQ

    Guanylate Cyclase Apoptosis Cancer
    ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells.
  • HY-125361
    Ganosporeric acid A

    Others Others
    Ganosporeric acid A, a natural product, is isolated from the ether-soluble fraction of the spores of Ganoderma lucidum (Curt.: Fr.) P. Karst. Ganosporeric acid A can be used for the research of liver injury.
  • HY-111516
    MGV354

    Guanylate Cyclase Inflammation/Immunology Cardiovascular Disease
    MGV354 is a soluble guanylate cyclase (sGC) activator with EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively.
  • HY-145453
    Propacetamol

    COX Inflammation/Immunology
    Propacetamol is a water-soluble acetaminophen precursor drug, which can be administered via non intestinal route. It is an analgesic used to treat postoperative pain, acute trauma and gastrointestinal disorders.
  • HY-147732
    sEH inhibitor-4

    Epoxide Hydrolase Inflammation/Immunology
    Intensive structural modification resulted in the identification of compound B15 as an effective sEH inhibitor with a value of 0.03 ± 0.01 nm, and the presence of soluble epoxide hydrolase (SEH) can reduce inflammation and pain.
  • HY-146343
    BMI-Glu

    Others Cancer Inflammation/Immunology
    BMI-Glu is a selective γ-glutamyl transpeptidase (GGT) fluorescent probe with a Km of 69.63 µM. BMI-Glu has high sensitivity, good water solubility and biocompatibility.
  • HY-W133967
    Calcium alginate

    Others Inflammation/Immunology
    Calcium alginate is a biopolymer that can be used for developing oral drug-delivery systems. Calcium alginate is a pH sensitive hydrogel stable in acidic media and soluble in basic media.
  • HY-P0281A
    TAT TFA

    HIV Infection
    TAT TFA (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus (HIV-1) and is a cell-penetrating peptide. TAT can increase the yields and the solubility of heterologous proteins.
  • HY-N9294
    2',4'-Dihydroxy-7-methoxy-8-prenylflavan

    Others Others
    2',4'-Dihydroxy-7-methoxy-8-prenylflavan (compound 6) is a compound isolated from a chloroform-soluble extract of dried Morus alba fruits.
  • HY-P0281
    TAT

    HIV Infection
    TAT (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1) and is a cell-penetrating peptide. TAT can increase the yields and the solubility of heterologous proteins.
  • HY-14779S1
    Riociguat-d6

    Guanylate Cyclase Cardiovascular Disease
    Riociguat-d6 (BAY 632521-d6) is the deuterium labeled Riociguat. Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
  • HY-117917
    (Rac)-MGV354

    Guanylate Cyclase Inflammation/Immunology Cardiovascular Disease
    (Rac)-MGV354 is the racemate of MGV354. MGV354 is a soluble guanylate cyclase (sGC) activator with EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively.
  • HY-N3942
    Glabranine

    HIV Influenza Virus Infection
    Glabranine, an flavonoid, is isolated from Tephrosia s.p, exerts a inhibitory effect in vitro on the dengue virus. Glabranine forms interaction with the soluble ectodomain of DENV type 2 (DENV2) E protein.
  • HY-117962
    (Rac)-BI 703704

    Guanylate Cyclase Metabolic Disease
    (Rac)-BI 703704 is a potent soluble guanylyl cyclase (sGC) activator. (Rac)-BI 703704 reduces progression of renal damage in the ZSF1 rat, and highlight the potential of sGC activation as an effective therapy for diabetic nephropathy.
  • HY-W013989
    1,3-Dicyclohexylurea

    Epoxide Hydrolase Cardiovascular Disease
    1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats.
  • HY-Y0319G
    Magnesium acetate tetrahydrate

    Endogenous Metabolite Others
    Magnesium acetate tetrahydrate is a hydrated form of anhydrous magnesium acetate salt. As a salt form of Magnesium, Magnesium acetate is one of the bioavailable forms of magnesium and forms a very water soluble compound. Magnesium acetate tetrahydrate can be used as an electrolyte supplementation or a reagent in molecular biology experiments.
  • HY-109039
    Praliciguat

    IW-1973

    Guanylate Cyclase Cardiovascular Disease
    Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase stimulator, enhances NO signaling, acts as a vasodilator. Praliciguat (IW-1973) stimulates sGC in HEK-293 cells with an EC50 of 197 nM.
  • HY-113926
    BAY 60-2770

    Guanylate Cyclase Cardiovascular Disease
    BAY 60-2770 is a potent, selective, and orally active soluble guanylyl cyclase (sGC) activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect.
  • HY-14779S2
    Riociguat-13C,d3

    BAY 632521-13C,d3

    Guanylate Cyclase Cardiovascular Disease
    Riociguat-13C,d3 (BAY 632521-13C,d3) is the 13C- and deuterium labeled Riociguat. Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
  • HY-103194
    KH7

    Adenylate Cyclase Others
    KH7 is a soluble adenylyl cyclase (sAC)-specific inhibitor, with IC50s of 3-10 μM toward both recombinant purified human sACt protein and heterologously expressed sACt in cellular assays. KH7 is also a cAMP inhibitor.
  • HY-14602
    Tramiprosate

    Homotaurine; 3-Amino-1-propanesulfonic acid

    Amyloid-β Cancer
    Tramiprosate (Homotaurine), an orally active and brain-penetrant natural amino acid found in various species of red marine algae. Tramiprosate binds to soluble Aβ and maintains Aβ in a non-fibrillar form. Tramiprosate is also a GABA analog and possess neuroprotection, anticonvulsion and antihypertension effects.
  • HY-108847
    Etanercept

    TNF Receptor Inflammation/Immunology
    Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
  • HY-135368
    8pyDTZ

    Others Others
    8pyDTZ is a pyridyl diphenylterazine (DTZ) analog and an ATP-independent pyridyl substrate of LumiLuc luciferase. 8pyDTZ exhibits spectrally shifted emission. 8pyDTZ has excellent biocompatibility and superior in vivo sensitivity. 8pyDTZ can be used for in vivo luminescence imaging.
  • HY-144287
    Glucokinase activator 3

    Glucokinase Endocrinology
    Glucokinase activator 3 is a potent and full Glucokinase (GK) activator with an AC50 of 38 nM. Glucokinase activator 3 has the potential for the research of type 2 diabetes.
  • HY-144738
    Dual FAAH/sEH-IN-1

    Epoxide Hydrolase FAAH Inflammation/Immunology
    Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase.
  • HY-132232
    GSK097

    Epigenetic Reader Domain Cancer
    GSK097 is a potent and selective Inhibitor of the second bromodomain (BD2) of the bromodomain and extra-terminal domain (BET) proteins. GSK097 displays 2000-fold selective for BD2 over BD1 (BRD4 data) with >1 mg/mL solubility in FaSSIF media.
  • HY-19644
    GSK2256294A

    GSK 2256294

    Epoxide Hydrolase Cardiovascular Disease
    GSK2256294A is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH.
  • HY-145831
    sEH/AChE-IN-1

    AChE Inflammation/Immunology Neurological Disease
    sEH/AChE-IN-1 (Compound 12a) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-1 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-1 has the potential for the research of Alzheimer's disease (AD).
  • HY-115400
    1V209

    TLR7 agonist T7

    Toll-like Receptor (TLR) Cancer
    1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity.
  • HY-145832
    sEH/AChE-IN-2

    AChE Inflammation/Immunology Neurological Disease
    sEH/AChE-IN-2 (Compound 12b) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-2 has the potential for the research of Alzheimer's disease (AD).
  • HY-113649
    AKB-6899

    HIF/HIF Prolyl-Hydroxylase Cancer
    AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects.
  • HY-135653A
    (Rac)-EC5026

    (Rac)-BPN-19186

    Epoxide Hydrolase Neurological Disease
    (Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a Ki of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB).
  • HY-146025
    Antitumor agent-F10

    Others Cancer
    Antitumor agent-F10 (Compound F10) is a camptothecin derivative. Antitumor agent-F10 is an orally–bioavailable and potent antitumor agent. Antitumor agent-F10 displays lower acute toxicity than SN-38 does and the solubility of F10 reached 9.86 μg/mL.
  • HY-116218
    Amelparib

    JPI-289

    PARP Neurological Disease Cardiovascular Disease
    Amelparib is a potent, orally active, and water-soluble inhibitor of PARP-1. Amelparib inhibits PARP-1 activity (IC50 =18.5 nmol/L) and cellular PAR formation (IC50 =10.7 nmol/L) in the nanomolar range. Amelparib is a potential neuroprotective agent. Amelparib has the potential for the research of acute ischaemic stroke.
  • HY-107201
    β-Cyclodextrin

    Influenza Virus Infection
    β-Cyclodextrin is a cyclic polysaccharide composed of seven units of glucose (α-D-glucopyranose) linked by α-(1,4) type bonds. β-Cyclodextrin has often been used to enhance the solubility of drugs. β-Cyclodextrin has anti-influenza virus H1N1 activities.
  • HY-126321
    RORγt agonist 1

    ROR Cancer
    RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC50 of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy.
  • HY-12379
    NS-2028

    Guanylate Cyclase Inflammation/Immunology
    NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor with IC50 values of 30 nM and 200 nM for basal and NO-stimulated enzyme activity. NS-2028 inhibits soluble Guanylyl Cyclase activity in homogenates of mouse cerebellum and neuronal NO synthase with IC50 values of 17 nM and 20 nM. NS-2028 inhibits 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells with an IC50 of 30 nM. NS-2028 is commonly used in the research of nitric oxide signaling pathways, it inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM). NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability.
  • HY-10220
    SF1126

    PI3K Apoptosis Cancer
    SF1126 is a relevant pan and dual first-in-class PI3K/BRD4 inhibitor, has antitumor and anti-angiogenic activity. SF1126 is an RGDS-conjugated LY294002 prodrug, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment. SF1126 induces cell apoptosis.
  • HY-136476D
    Ga(III) protoporphyrin IX

    Bacterial Infection
    Ga(III)protoporphyrin-IX is a model for the key interporphyrin interactions in malaria pigment. Ga(III)protoporphyrin-IX acts as a potent antibacterial against gram-negative, gram-positive, and acid-fast bacteria. Ga(III)protoporphyrin-IX is readily soluble in methanol (MeOH). Ga(III)protoporphyrin IX are as malarial pigment analogues for drug development and as potential antibacterial agents.
  • HY-14602S
    Tramiprosate-d6

    Homotaurine-d6; 3-Amino-1-propanesulfonic acid-d6

    Amyloid-β Cancer
    Tramiprosate-d6 (Homotaurine-d6) is the deuterium labeled Tramiprosate. Tramiprosate (Homotaurine), an orally active and brain-penetrant natural amino acid found in various species of red marine algae. Tramiprosate binds to soluble Aβ and maintains Aβ in a non-fibrillar form. Tramiprosate is also a GABA analog and possess neuroprotection, anticonvulsion and antihypertension effects.
  • HY-110120
    DSR-6434

    Toll-like Receptor (TLR) Cancer
    DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist, with EC50s of 7.2 nM and 4.6 nM for human and mice TLR7, respectively. DSR-6434 has a strong antitumor effect.
  • HY-19323A
    (S)-Ceralasertib

    (S)-AZD6738

    ATM/ATR Cancer
    (S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC50 of 2.578 nM. (S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. (S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition.
  • HY-128171
    Diflapolin

    FLAP Epoxide Hydrolase Inflammation/Immunology
    Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC50s of  30 and 170 nM, respectively, and suppressed the activity of isolated sEH (IC50=20 nM).
  • HY-125021
    2BAct

    Eukaryotic Initiation Factor (eIF) Neurological Disease
    2BAct is a highly selective, and orally active eIF2B (eukaryotic initiation factor 2B) activator with an EC50 of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct is able to penetrate the central nervous system (CNS). 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB (HY-12495).
  • HY-16643
    Linerixibat

    GSK2330672

    Others Metabolic Disease Inflammation/Immunology
    Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment.
  • HY-146704
    COX-2/sEH-IN-1

    Epoxide Hydrolase COX Cardiovascular Disease
    COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
  • HY-135795
    1-Cyclohexyl-3-dodecyl urea

    CDU; N-Cyclohexyl-N-dodecyl urea; NCND

    Epoxide Hydrolase Metabolic Disease Cardiovascular Disease
    1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) is a highly selective soluble epoxide hydrolase (sEH) inhibitor. 1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) increases epoxyeicosatrienoic acids (EETs) levels and lowers blood pressure in angiotensin II (Ang II) hypertension.
  • HY-146523
    TRK-IN-17

    Trk Receptor Cancer
    TRK-IN-17 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-17 has the potential for the research of cancer diseases (extracted from patent WO2021148807A1, compound 3).
  • HY-124623
    DNDI-8219

    Parasite Infection
    DNDI-8219 (compound 58) is a potent selective and orally active trypanocidal agent, possessing inhibitory activity against Trypanosoma cruzi (T. cruzi) with an IC50 of 0.4 μM. DNDI-8219 has low cytotoxicity (L6 cells IC50 > 100 μM). DNDI-8219 can effectively cure chronic T. cruzi infection and markedly reduce parasite burdens in mouse model. DNDI-8219 has good solubility, metabolic stability and safety.
  • HY-146524
    TRK-IN-18

    Trk Receptor Cancer
    TRK-IN-18 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2021148805A1, compound 7).
  • HY-50751
    Linifanib

    ABT-869; AL-39324

    PDGFR VEGFR FLT3 c-Fms c-Kit Autophagy Apoptosis Cancer
    Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis.
  • HY-14442
    ML 10302 hydrochloride

    5-HT Receptor Metabolic Disease Neurological Disease
    ML 10302 hydrochloride is a potent and selective 5-HT4 receptor agonist, with an EC50 of 4 nM. ML 10302 hydrochloride displays more than 680-fold selectivity over 5-HT3 receptor in binding assay.
  • HY-144122
    HIV-1 inhibitor-15

    HIV Infection
    HIV-1 inhibitor-15 (compound 9d) is a highly potent and broad-spectrum HIV-1 inhibitor. HIV-1 inhibitor-15 has inhibitory activity against HIV-1 WT, L100I, K103N, Y181C, E138K with EC50s of 1.7 nM, 4 nM, 2 nM, 6 nM and 9 nM, respectively. HIV-1 inhibitor-15 has good solubility, safety profiles and favorable oral bioavailability.
  • HY-144123
    HIV-1 inhibitor-16

    HIV Infection
    HIV-1 inhibitor-16 (compound 7a) is a highly potent HIV-1 inhibitor with an EC50 value of 1.3 nM for HIV-1 WT. HIV-1 inhibitor-16 also has certain inhibitory activity against HIV-1 K103N, E138K, Y181C and L100I strains with EC50s of 5.4 nM, 9.2 nM, 22 nM and 35 nM. HIV-1 inhibitor-16 has favorable solubility and liver microsome stability, and does not exhibit apparent CYP enzymatic inhibitory activity or acute toxicity.